Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Cardiovascular outcomes of patients with FL & DLBCL treated with doxorubicin-based chemotherapy

Vincent Camus • 14 Jun 2023
ICML 2023
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma R-CHOP

Vincent Camus, MD, University of Rouen, Rouen, France, discusses a retrospective analysis which evaluated the outcomes of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) receiving standard R-CHOP-like chemotherapy in the frontline setting. Dr Camus comments on the cardiovascular events observed in these patients and further highlights the importance of monitoring patients before, during, and after treatment for cardiovascular toxicities. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Vincent Camus

2:42
Final analysis of the Ro-CHOP trial: romidepsin plus CHOP vs CHOP in previously untreated PTCL
Vincent Camus • 14 Jun 2023
2:15
Using GEP to molecularly characterize & predict the outcomes of patients with PMBCL
Vincent Camus • 14 Jun 2023
1:51
10-year follow-up of the LNH03-6B trial: outcomes of older patients with DLBCL treated with R-CHOP
Vincent Camus • 14 Jun 2023

Related Videos

1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
2:45
The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi • 24 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals